Determinants of Disability in Multiple Sclerosis: An Immunological and MRI Study
Table 5
Percentages of MBP-stimulated cytokine producing blood cells from patients with different MS phenotypes.
Cell type
BMS
RRMS
SPMS
BMS versus
RRMS
BMS versus
SPMS
SPMS versus
RRMS
LS mean
95% CL
LS mean
95% CL
LS mean
95% CL
CD4+IL17+
0.07
−0.02
0.21
0.09
−0.07
0.24
0.12
0.02
0.23
ns
ns
ns
CD4+IFN+
0.02
−0.14
0.17
0.16
−0.09
0.42
0.13
−0.08
0.34
ns
ns
ns
CD14+IL12p35+
2.02
0.90
3.13
0.93
−0.80
2.65
1.17
−0.08
2.42
ns
ns
ns
CD14+IL6+
15.24
10.53
19.96
1.72
−4.82
8.27
0.64
−4.03
5.32
0.004
<0.0001
ns
CD4+IL13+
0.16
0.13
0.20
0.12
0.06
0.17
0.11
0.07
0.15
ns
ns
ns
CD4+IL25+
0.48
0.40
0.56
0.60
0.48
0.72
0.18
0.08
0.27
ns
<0.0001
<0.0001
CD14+IL10+
13.14
4.78
21.50
11.80
−0.05
23.64
20.32
11.32
29.32
ns
ns
ns
CD14+TGF+
2.02
−0.63
4.66
5.52
1.66
9.38
4.83
2.03
7.62
ns
ns
ns
CD4+BDNF+
1.77
−2.31
5.84
9.76
2.81
16.71
0.61
−3.68
4.90
ns
ns
ns
Data are reported as least squares (LS) means and 95% confidence limits. Between-group comparison values were corrected with Tukey-Kramer and the following variables were taken as covariates: therapy (dichotomic variable: yes/no), age, and gender; ns: not significant.
